Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide Coadministered With Rosuvastatin in Adults With Hyperlipidemia
NCT07216482Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of enlicitide in hyperlipidemia (4 arms), sponsored by Merck & Co. Primary endpoint: Mean Percent Change from Baseline in Low-Density Lipoprotein Cholesterol at 8 weeks. Started Nov 2025; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07216482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216482.